Obesity

Obesity & Metabolic Disorder

Obesity & Metabolic Disorder

In focusing on appetite suppression and pace of digestion for weight loss, the current therapeutic solutions don't address the root causes of obesity or underlying metabolic issues.
Canary Cure Therapeutics utilizes dual siRNA technology to precisely silence key genes specifically in adipose tissue to:
  • Reduce signals promoting fat storage by silencing genes involved in adipogenesis
  • Promote metabolic rewiring towards higher energy expenditure, through increased thermogenesis.
  • Transform white adipose tissue (WAT) into beige adipose tissue (browning) by silencing a gene which suppresses the thermogenic program.
  • Reduce hepatic steatosis (fatty liver) and systemic inflammation.
  • Induce significant weight loss, primarily through fat mass reduction, while preserving lean body mass.
Limitations of Current Obesity Treatments:
  • Up to 40% loss of lean muscle mass: unhealthy weight loss, compromising strength, metabolism, and long-term health outcomes
  • Focus on symptoms, not health: primarily suppressing appetite, failing to address the underlying metabolic issues or optimize body composition
  • Durability & adherence issues: Weekly injections and frequent side effects reduce adherence, while weight regain is common after stopping treatment

Canary Cure’s Solution:

  • Targeting fat, building muscle: Canary’s siRNA therapy is uniquely designed to induce substantial weight loss primarily through fat reduction while simultaneously increasing lean muscle mass by reprogramming white adipose tissue.
  • Transforming body composition: promoting healthy weight loss and improving body composition that enhances overall metabolic function and physical capability.
  • Metabolic restoration, not just weight loss: by converting white fat to energy-burning beige fat, Canary’s gene silencing therapy increases energy expenditure and restores metabolic health, addressing root causes beyond appetite.

Canary’s Reprogram Platform

Canary’s Reprogram Platform represents a breakthrough in obesity treatment by transforming inactive white fat into metabolically active beige fat. Our flagship therapy, CCT-217, and developing pipeline assets target the root causes of metabolic dysfunction beyond appetite control.
Energy-storing human white adipocytes before treatment ​

Energy-storing human white adipocytes before treatment ​

Transformation towards fat burning human beige adipocyte

Transformation towards fat burning human beige adipocyte

CCT-217’s Remarkable Ability to Beige Human White Fat

This reprogramming of human fat cell to create metabolically active cells represents a significant breakthrough in translational adipose tissue research with profound implications for obesity therapeutics.
The first microscopic field reveals a dense population of human adipocytes which stores energy. The second picture reveals adipocytes that have undergone remarkable morphological transformation, following CCT-217 siRNA treatment into smaller, more numerous lipid droplets, in just 72 hours. The increased multilocularity (multiple small lipid droplets within cells) is characteristic of enhanced thermogenic capacity.
Beige adipose tissues predominantly functions to dissipate energy surplus, increasing resting energy expenditure and counteracting obesity. This is precisely the mechanism of action in Canary’s CCT-217 which treats obesity through the transformation of our white fat into metabolic active, fat burning beige fat.
Our Focus:
  • Obesity: Our novel siRNA therapeutics target the endocannabinoid and energy expenditure systems, promoting the browning of white fat to increase metabolism and facilitate sustainable healthy weight loss. Unlike conventional approaches, our therapies prioritize fat loss, preservation of lean body mass and body composition improvement. With the convenience of less frequent dosing and better safety profile, this gene silencing therapy offers a promising solution for individuals battling obesity and its associated metabolic complications.
  • Metabolic dysfunction-associated steatohepatitis (MASH): formerly known as nonalcoholic steatohepatitis (NASH), a severe form of fatty liver disease characterized by inflammation and liver damage which there is an urgent need for effective therapies. Canary’s siRNA mechanism of action, which promotes beigeing of white fat to improves metabolic function, has shown promise in reducing liver fat accumulation and inflammation, suggesting its potential to address the underlying metabolic dysfunction associated with MASH.
  • Metabolic Dysfunction:Leveraging its ability to starve hypermetabolic cells, our primary drug candidate, CCT217, precisely targets key pathways to significantly amplify the activity of metabolically active beige fat cells - specialized cells that excel at consuming nutrients and expending energy. By influencing metabolic adaptability, this siRNA therapy re-establishes balanced resource distribution within environments susceptible to abnormal cell growth like cancer. This dual-action mechanism not only cuts off fuel supplies for hyperactive metabolic states but also strengthens overall metabolic health by improving how the body responds to insulin and manages lipids. This is a pioneering approach for conditions caused by rigid metabolism.
  • Rare Pediatric Obesity: Conditions such as Prader-Willi Syndrome (PWS) and hypothalamic obesity are devastating genetic diseases in which children suffer from insatiable hunger, rapid weight gain, and severe loss of muscle and cognitive function from the earliest stages of life — yet existing treatments address only isolated symptoms without targeting the underlying genetic and metabolic causes of disease. We are developing a dual RNA therapeutic platform that directly modulates the gene expression pathways driving these conditions, offering a fundamentally different approach from the symptomatic strategies that families and clinicians currently rely on. Our preclinical program has demonstrated significant weight reduction while increasing lean body mass — evidence of true anabolic body re- composition. This positions us uniquely in a space with clear unmet need, strong regulatory incentives and a dedicated community of families, clinicians and advocates.
By addressing both energy expenditure and appetite control, Canary’s proprietary combinatorial therapy holds the potential to overcome the limitations of single-target approaches and achieve more effective and sustained weight loss.
Our goal is metabolic stability and long-term health.
Thermogenesis

Thermogenesis

Harnessing the Power of Thermogenesis to Promote Metabolic Health

Our bodies have a remarkable ability to regulate energy balance and maintain a healthy weight. One crucial process in this regulation is thermogenesis, the conversion of energy into heat, our body’s natural mechanism in regulating energy. We use advanced lipid nanoparticle (LNP) technology to deliver therapeutic molecules precisely to the tissues responsible for generating heat. By increasing thermogenesis (fat burning) and lipolysis (fat breakdown), we can increase energy expenditure and promote fat loss.
In activating specific pathways involved in thermogenesis, Canary’s patent pending therapy aims to boost the body's own ability to burn calories and utilize stored fat.
Batokines’ Signaling Power
CCT-217 uses a ”act locally, treat systemically" approach where the therapeutic agent remains localized at the injection site while the biological effects spread throughout the body through the signaling pathways of batokines - bioactive signaling molecules secreted by human beige adipocytes
Batokines affect multiple tissues:
  • Liver: Reducing steatosis & improving lipid metabolism
  • Visceral fat: Reducing accumulation in retroperitoneal, mesenteric, and gonadal depots
  • Muscle: Preserving and enhancing lean mass
  • Bone marrow: Reversing adiposity
Monogenic Obesity

Monogenic Obesity

Pioneering RNA Therapeutics for Severe Pediatric Obesity

Rare pediatric obesity is a catastrophic problem for children. Obesity caused by gene mutations, such as in Prader-Willi Syndrome (PWS), causes children to have an insatiable appetite and rapid weight gain. The early-onset obesity can cause cardiovascular and metabolic comorbidities and is associated with increased mortality.
PWS, a rare, complex genetic disorder requiring multi-disciplinary care currently has no cure. Our lead product, CCT-987 is designed to directly correct the peripheral adipose biology. By delivering a payload of CB1R siRNA and Leptin mRNA directly to subcutaneous adipose tissue. The dual RNA therapy achieves true metabolic restoration - driving profound improvements in the fat-to-muscle ratio and systemic metabolic parameters that far exceed the capabilities of centrally acting agents.
"While the field has made vital strides in managing the behavioral symptoms of PWS, the structural and metabolic deficits have remained largely out of reach. CCT-987 changes that paradigm. A treatment that promotes weight loss while actively enhancing lean mass isn't just an improvement—it's a fundamentally different therapeutic proposition.

For these patients, achieving metabolic restoration and reversing profound muscle weakness could be absolutely life-changing.”
- Dr. Jennifer Miller, MD
Renowned Clinician and KOL in Pediatric Endocrinology and PWS
Every child deserves the opportunity to thrive. By developing safe and effective RNA therapies for severe early-onset obesity, we strive to:

Empower Children

Help children achieve a healthy weight and improve their quality of life.

Support Families

Provide families with hope and a path towards better health for their children.

Advance Science

Drive innovation in RNA therapeutics and pave the way for new treatment options.

Pioneering RNA Therapy

We are revolutionizing healthcare by harnessing the power of cutting-edge RNA therapies to develop and deliver innovative treatments that addresses the root causes of diseases. We are committed to fostering a culture of scientific excellence and collaboration to create life-changing treatments that are safe, effective, and accessible to all.

Disclaimer: Canary Cure Therapeutics Inc’s website includes future planned care offerings, that are currently in development and are subject to regulatory approval before they are able to be commercialized

Quick Links

Useful Links

Quick Contact

  • 5063 N Service Road, Suite 100, Burlington, ON, Canada
  • info@canarycure.com

Follow Us

Twitter
Copyright © 2023 Canary Global Inc. All rights reserved.